2002
DOI: 10.2106/00004623-200212000-00004
|View full text |Cite
|
Sign up to set email alerts
|

Osteonecrosis of the Femoral Head After Solid Organ Transplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
40
0
4

Year Published

2007
2007
2021
2021

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 87 publications
(48 citation statements)
references
References 25 publications
4
40
0
4
Order By: Relevance
“…It is not related to the cumulative dosage of MP and tacrolimus or the early withdrawal of MP. Our findings are consistent with the reports by others, 4,8,[20][21][22][23] suggesting that symptomatic ONFH is rather uncommon in this cohort of liver transplant patients on current immunosuppressive protocols. The underlying mechanism of osteonecrosis in liver transplant recipients is complex, which may be related to corticosteroid use, hypercoagulable state, or hypofibrinolysis.…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…It is not related to the cumulative dosage of MP and tacrolimus or the early withdrawal of MP. Our findings are consistent with the reports by others, 4,8,[20][21][22][23] suggesting that symptomatic ONFH is rather uncommon in this cohort of liver transplant patients on current immunosuppressive protocols. The underlying mechanism of osteonecrosis in liver transplant recipients is complex, which may be related to corticosteroid use, hypercoagulable state, or hypofibrinolysis.…”
Section: Discussionsupporting
confidence: 93%
“…Marston and associates reported the incidence of ONFH as 20% one year after renal transplant. 4 In other studies, however, the incidence of ONFH was as low as 1.5% to 4.6% in liver, kidney, and heart transplant recepients. [5][6][7][8] In addition, some rare conditions also should be considered, including calcineurin-inhibitor-induced pain syndrome (CIPS).…”
Section: Introductionmentioning
confidence: 84%
“…It has been demonstrated that cumulative intravenous methylprednisolone at doses of >2 g for >3 months significantly increased the risk for ON [16]. The frequent inclusion of corticosteroids in treatment protocols for various medical conditions, such as acute lymphoblastic leukemia (ALL), various lymphomas, and either solid organ or bone marrow transplantation, clearly put these patients at an increased risk for ON [17][18][19][20][21][22][23][24]. In a prospective MRI study, the incidence of ON associated with corticosteroid therapy was significantly higher in systemic lupus erythematosus (SLE) patients than in non-SLE patients (37 versus 21 %, P=0.001) [25•].…”
Section: Corticosteroidsmentioning
confidence: 99%
“…Risk factors for ON were age (adolescents and adults compared to pediatric patients), high daily corticosteroid dosage (>40 mg/day), SLE patient compared to non-SLE patient, and male gender. In solid organ transplantation patients, Marston and Cheng [20] prospectively analyzed 52 patients (103 hips) and reported the prevalence of osteonecrosis of the femoral head as 11 % at 1 year after the transplantation. In patients with acute lymphoblastic leukemia treated with multiple, prolonged courses of corticosteroid, the Children's Cancer Group reported that 111 of 1409 patients had ON with a 3-year life-table estimated incidence of 9.3 % [21].…”
Section: Corticosteroidsmentioning
confidence: 99%
“…μετά από μεταμόσχευση νεφρού ή άλλων οργάνων) (Fink 1998, Marston 2002, το κάπνισμα, η ακτινοβολία (Cramer 2002), η χημειοθεραπεία (Dawson 2001), η νόσος του Gaucher (Katz 1996, Rodrigue 1999, η θρομβοφιλία (Glueck 2001) καθώς και κάποιοι άλλοι σπανιότεροι παράγοντες (Ries 2002). Η οστεονέκρωση που δεν συσχετίζεται με κάποιο από τους γνωστούς αιτιολογικούς παράγοντες χαρακτηρίζεται ως ιδιοπαθής.…”
Section: αιτιοπαθογένεια -παθοφυσιολογίαunclassified